FDA Approves Albuterol Sulfate ANDA219409 from Cipla
The FDA has approved ANDA219409 for Albuterol Sulfate submitted by Cipla.
Published: June 20, 2026
Updated: June 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Respiratory / Bronchodilator
Asset: Cipla
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Cipla
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Cipla's ANDA219409 for Albuterol Sulfate introduces a new competitor in the respiratory market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications of this entry on their existing products and strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market launch timelines and pricing strategies from Cipla and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.